NOVO NORDISK B A/S
看多

NVO absolutely sweet level

399
This downturn is attributed to disappointing clinical trial results for some of its drugs and concerns over potential tariffs affecting Denmark. Additionally, competition from Eli Lilly's successful weight-loss drug trials has impacted investor confidence. ​

Despite these challenges, analysts note that Novo Nordisk maintains strong fundamentals and a positive long-term outlook, particularly in its core areas of diabetes and obesity treatments.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。